Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/1264
Title: | Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. |
Epworth Authors: | Prince, Miles |
Other Authors: | van der Weyden, Carrie Pileri, Stefano Feldman, Andrew Whisstock, James |
Keywords: | CD30 Hematopoietic Malignancies Brentuximab Vedotin BV Tumor Marker Therapeutic Target Tumor Necrosis Factor Receptor TNFR Pathogenesis Lymphomagenesis Cell Survival Efficacy Hodgkin Lymphoma Peripheral T-Cell Lymphoma Cutaneous T-Cell Lymphoma Disease Control Anaplastic Large Cell Lymphoma History Insight Future Directions Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia |
Issue Date: | Sep-2017 |
Publisher: | Nature Publishing Group |
Citation: | Blood Cancer J. 2017 Sep 8;7(9):e603 |
Abstract: | CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Given the restriction of CD30 to certain tumor types, the logical extension of this has been to attempt to exploit it as a therapeutic target. The efficacy of naked anti-CD30 antibodies in practice was, however, modest. Moreover, combinations with bacterial toxins and radioimmunoconjugates have also had limited success. The development of the antibody-drug compound brentuximab vedotin (BV), however, has rejuvenated interest in CD30 as a tumor target. Phase I and II clinical trials in Hodgkin lymphoma, peripheral T-cell lymphoma, cutaneous T cell lymphoma, and even CD30-expressing B-cell lymphomas, have shown the compound is well tolerated, but more importantly, able to deliver meaningful disease control even in patients with multiply relapsed or refractory disease. FDA approval has been granted for its use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. A recent phase III trial of BV in cutaneous T-cell lymphoma has confirmed its superiority to standard of care therapies. In this manuscript, we explore the history of CD30 as a tumor marker and as a therapeutic target, both in the laboratory and in the clinic, with a view to understanding future avenues for further study. |
URI: | http://hdl.handle.net/11434/1264 |
DOI: | 10.1038/bcj.2017.85 |
PubMed URL: | https://www.ncbi.nlm.nih.gov/pubmed/28885612 |
ISSN: | 2044-5385 |
Journal Title: | Blood Cancer Journal |
Type: | Journal Article |
Affiliated Organisations: | Department of Haematology, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia Haematopathology Unit, European Institute of Oncology, Milan, Italy Bologna University School of Medicine, Bologna, Italy Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA ARC Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia |
Type of Clinical Study or Trial: | Review |
Appears in Collections: | Cancer Services |
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.